The review period is aprx a year in Europe and is not included as preparation is an additional 6-9 months.
Timelines are long in the drug approval process and investors should have facts, not skewing of info to pad
your rah rah post
Will Lewis hopefully optomistic mid 2015 launch of Arikace in Europe assumes no delays or problems such as shareholders experienced with rat data. Delays during the approval process happen often.
As far as the US,,again your reality is "maybe" cross check reveals your /ID nonsense. get real clown....